Search
"I had never heard of invasive Streptococcus A disease before, and I was shocked to hear that it is actually three times more common than meningococcal disease and just as deadly yet there is no vaccine to protect against it."
Latest news & events at the Wesfarmers Centre of Vaccines & Infectious Diseases.
Researchers from the Wesfarmers Centre of Vaccines and Infectious Diseases at The Kids Research Institute Australia have shared their expertise with the community in Cockburn, covering topics ranging from respiratory disease in babies to recurring ear infections in kids.
Clinical Professor Tobias Strunk, Dr Andrew Currie and their Neonatal Infection and Immunity Team have become the newest members of the Wesfarmers Centre of Vaccines and Infectious Diseases.
STopping Acute Rheumatic Fever Infections to Strengthen Health (STARFISH) brings together a diverse and multidisciplinary research team to investigate the most effective environmental health initiatives (EHIs) aimed at reducing Strep A infections and prevent Acute Rheumatic Fever (ARF).
Outputs from the Strep A Burden of Disease Working Group
Streptococcus A is a bacterium often found in the throat and on the skin.
Streptococcus pyogenes (Group A Streptococcus, Strep A) is a Gram-positive bacterium and one of the most significant global bacterial pathogens, with disproportionate disease burden affecting low and middle-income countries. Despite substantial mortality and immune sequelae caused by Strep A, no licensed vaccines exist, and correlates of protection remain unestablished.
The transmission of Group A Streptococcus (Strep A) through respiratory droplets has been considered the dominant mode of transmission to date; however, little is known about the relative contribution of other modes of transmission. This review systematically summarises the contemporary evidence regarding the transmission of Strep A.
Controlled human infection (CHI) models can provide insights into transmission of pathogens such as Streptococcus pyogenes (Strep A). As part of the Controlled Human Infection with Penicillin for Streptococcus pyogenes (CHIPS) trial, we explored the potential for transmission among participants deliberately infected with the Strep A emm75 strain.